Safety Maintained After Discontinuation in Stable Patients
Randomized Clinical Trial of 2,540 Korean Patients Published in NEJM
Provides Evidence for Reconsidering Long-Term Medication Therapy

A clinical trial has found that beta blockers, which were traditionally considered a lifelong medication after experiencing a myocardial infarction, may be safely discontinued in some patients. For stable patients, stopping the medication did not show a significant difference in treatment efficacy or safety compared to continued use.

Researchers who verified the necessity of long-term beta-blocker use in myocardial infarction patients. Samsung Seoul Hospital

Researchers who verified the necessity of long-term beta-blocker use in myocardial infarction patients. Samsung Seoul Hospital

View original image

Samsung Seoul Hospital announced on March 31 that the research team led by Professor Han Jooyong of the Department of Cardiology has published the results of the 'SMART-DECISION' study, which evaluated the safety of discontinuing beta blockers in stable post-myocardial infarction patients, in the international journal The New England Journal of Medicine (NEJM).


Beta blockers have long been used as standard therapy to reduce the risk of recurrence and mortality. However, as treatment outcomes have improved with procedures such as coronary intervention, there has been ongoing debate about whether long-term use is necessary for patients with preserved cardiac function.


To address this question, the research team conducted a randomized clinical trial. From April 2021 to April 2023, the study enrolled 2,540 patients from 25 medical institutions across Korea who had taken beta blockers for more than one year after myocardial infarction, had a left ventricular ejection fraction of at least 40%, and did not have heart failure. The participants were randomly assigned in a 1:1 ratio to either the discontinuation group or the continuation group. The median follow-up period was 3.1 years.


The primary endpoints—comprising all-cause mortality, recurrent myocardial infarction, and hospitalization for heart failure—were observed in 58 patients in the discontinuation group and 74 patients in the continuation group. Statistically, the discontinuation strategy was found to be non-inferior compared to continued therapy. There were also no significant differences between the two groups in detailed indicators such as recurrence of myocardial infarction.


The research team explained, "This study suggests that long-term beta blocker therapy may not be strictly necessary for stable patients with preserved cardiac function."



However, they added that the generalizability of the findings is limited as the study was conducted on Korean patients. Further validation in more diverse populations will be needed in the future.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing